Drug Profile
Research programme: nerve regeneration therapeutics - Amsterdam Molecular Therapeutics
Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator Amsterdam Molecular Therapeutics
- Developer Amsterdam Molecular Therapeutics; Galapagos NV; Netherlands Institute for Brain Research; Vrije Universiteit
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 15 Dec 2005 Preclinical trials in Neurological disorders in Netherlands (unspecified route)